Danaher Corporation

NYSE:DHR

Medical - Diagnostics & Research

Healthcare
$228.41 -0.21%

-$0.38 today

Market cap
$160.69B
Beta
0.83
P/E (TTM)
34.0
EPS (TTM)
$5.21
Dividend yield
0.77%
52W Low $160.93High $242.80

Volume 2.92M

Average 4.52M

DHR Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Danaher CorporationNYSE: DHR

Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026

Cost of revenue grows, but more slowly than its trailing trend

Q3 FY2026 cost of revenue of $2.72B rose 7.4% year over year, behind the +12.9% change in trailing-twelve-month cost of revenue. Sequentially, it rose 2.4% from the prior quarter. Over 3 fiscal years it compounded at -2.8% a year.

Context

  • Cost of revenue amounted to 39.1% of revenue in FY2025, down 1.4 pp from a year earlier.
  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +7.4% toward the trailing-twelve-month pace of +12.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$2.72B+2.4% QoQ
Last fiscal yearDec 2025
$9.6B-0.7% YoY
LTMSep 2026
$10.6B+12.9% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.4%——
1 year-0.7%——
3-year CAGR-2.8%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
9.6B USD
Year-over-year change
-0.7%
4-year CAGR
-4.4%

Cost of Revenue vs competitors

How DHR compares with its peers on the latest reported figures

  • DHR's LTM Sep 2026 cost of revenue of $10.6B is the 2nd highest of the 9 companies compared; the peer median is $1.79B.
  • Its year-over-year change of +12.9% is the 2nd highest of 9, against a peer median of +6.7%.
  • Cost of revenue amounts to 41.4% of revenue for DHR, versus a peer median of 47.1%.
DHR Competitors Peer median
Cost of Revenue for DHR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TMOThermo Fisher Scientific Inc.LTM Sep 2026$27.73B +6.5%+0.5%58.6%
DHRDanaher CorporationLTM Sep 2026$10.6B +12.9%-2.8%41.4%
AAgilent Technologies, Inc.LTM Jul 2026$3.41B +6.8%+1.9%46.3%
WATWaters CorporationLTM Jul 2026$2.29B +83.1%+2.3%49.2%
BRKRBruker CorporationLTM Jun 2026$1.87B +4.7%+14.9%53.3%
MTDMettler-Toledo International Inc.LTM Jun 2026$1.72B +7.4%-0.8%41.6%
ILMNIllumina, Inc.LTM Jun 2026$1.49B +6.0%-3.6%33.2%
RVTYRevvity, Inc.LTM Jul 2026$1.39B +8.5%-4.8%47.9%
QGENQiagen N.V.LTM Jun 2026$801.85M +6.1%+1.8%38.2%
Peer median (excluding DHR) $1.79B+6.7%+1.2%47.1%

Competitors are the stored peer set for DHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue29.45B26.64B23.89B23.88B24.57B
Cost of Revenue11.5B10.46B9.86B9.67B9.6B
Gross Profit17.95B16.19B14.03B14.21B14.97B
Gross Margin61.0%60.8%58.7%59.5%60.9%
Research & Development1.74B1.53B1.5B1.58B1.6B
Selling, General & Admin8.16B7.12B7.25B7.44B8.24B
Operating Expenses9.9B8.65B8.76B9.02B9.83B
Depreciation & Amortization2.17B2.13B2.17B2.35B2.45B
EBITDA10.01B9.49B7.5B7.28B6.95B
EBITDA Margin34.0%35.6%31.4%30.5%28.3%
Operating Income8.05B7.54B5.28B5.18B5.14B
Operating Margin27.3%28.3%22.1%21.7%20.9%
Interest Income11M41M303M117M30M
Interest Expense241M207M289M278M265M
Other Income / Expenses(452M)(390M)(235M)(538M)(904M)
Income Before Tax7.6B7.15B5.04B4.65B4.23B
Pre-Tax Margin25.8%26.8%21.1%19.5%17.2%
Income Tax Expense1.25B818M823M747M619M
Net Income6.43B7.21B4.76B3.9B3.61B
Net Margin21.8%27.1%19.9%16.3%14.7%
EPS (Basic)8.779.806.445.335.07
EPS (Diluted)8.619.646.385.295.04
Weighted Avg Shares714.6M725.1M736.5M731M707.3M
Weighted Avg Shares (Diluted)736.8M737.1M743.1M737.2M711M

Danaher Corporation

NYSE:DHR

Intrinsic Alpha fair value

Locked

Current Price

$228.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.